

# Sascha Troschke-Meurer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5356118/publications.pdf>

Version: 2024-02-01

10  
papers

179  
citations

1307594

7  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

301  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD <sub>2</sub> antibody ch14.18/CHO. <i>Oncolmmunology</i> , 2017, 6, e1343775.	4.6	53
2	Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. <i>Oncolmmunology</i> , 2016, 5, e1235108.	4.6	39
3	GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 577-585.	2.9	18
4	Inflammatory response and treatment tolerance of long-term infusion of the anti-GD <sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26967.	1.5	15
5	Low CD4 <sup>+</sup> /CD25 <sup>+</sup> /CD127 <sup>+</sup> regulatory T cell- and high INF- $\gamma$ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. <i>Oncolmmunology</i> , 2019, 8, 1661194.	4.6	14
6	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEX Phase 2 Trial. <i>Cancers</i> , 2018, 10, 387.	3.7	13
7	Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 690467.	4.8	10
8	Reduction of CD11b <sup>+</sup> myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD <sub>2</sub> antibody ch14.18/CHO. <i>Oncolmmunology</i> , 2020, 9, 1836768.	4.6	6
9	Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy. <i>Frontiers in Pediatrics</i> , 2020, 8, 582820.	1.9	6
10	Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. <i>PLoS ONE</i> , 2018, 13, e0207320.	2.5	5